We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen (FATI-01)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01714414
First Posted: October 26, 2012
Last Update Posted: April 28, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
European and Developing Countries Clinical Trials Partnership (EDCTP)
German Federal Ministry of Education and Research
National Institute for Medical Research, Tanzania
Treichville Academic hospital center, Division of infectious and tropical diseases (SMIT)
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Kumasi Centre for Collaborative Research (KCCR)
Bernhard Nocht Institute for Tropical Medicine
Pharmaceutical Company (Chiracon GmbH)
Pharmaceutical Company (STADA Vietnam Joint Venture Co. Ltd.)
Information provided by (Responsible Party):
Michael Hoelscher, Ludwig-Maximilians - University of Munich
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2017
  Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)